Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has been given a consensus rating of “Buy” by the fourteen ratings firms that are covering the company, MarketBeat.com reports. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $77.29.
A number of research firms have recently weighed in on AGIO. SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $80.00 price target (up from $68.00) on shares of Agios Pharmaceuticals in a research note on Tuesday. Oppenheimer Holdings, Inc. set a $75.00 target price on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, June 11th. Credit Suisse Group reissued an “outperform” rating and set a $61.00 target price on shares of Agios Pharmaceuticals in a research report on Tuesday, April 18th. Zacks Investment Research raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, April 28th. Finally, Janney Montgomery Scott reissued a “hold” rating on shares of Agios Pharmaceuticals in a research report on Tuesday, August 1st.
In other news, CEO David P. Schenkein sold 27,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 2nd. The shares were sold at an average price of $59.95, for a total transaction of $1,618,650.00. Following the completion of the sale, the chief executive officer now owns 3,000 shares of the company’s stock, valued at $179,850. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Lewis Clayton Jr. Cantley sold 2,036 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $47.10, for a total transaction of $95,895.60. Following the sale, the director now directly owns 91,206 shares of the company’s stock, valued at approximately $4,295,802.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 79,120 shares of company stock valued at $4,557,207. Corporate insiders own 10.55% of the company’s stock.
Several hedge funds have recently bought and sold shares of the company. C WorldWide Group Holding A S purchased a new stake in Agios Pharmaceuticals during the first quarter valued at $105,000. Bank of Montreal Can raised its stake in shares of Agios Pharmaceuticals by 11.7% in the first quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 216 shares in the last quarter. Blue Sky Asset Management LLC bought a new stake in shares of Agios Pharmaceuticals during the first quarter worth $129,000. Russell Investments Group Ltd. raised its stake in shares of Agios Pharmaceuticals by 163.9% in the first quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock worth $149,000 after buying an additional 1,583 shares in the last quarter. Finally, Advantage Investment Management LLC raised its stake in shares of Agios Pharmaceuticals by 109.7% in the first quarter. Advantage Investment Management LLC now owns 3,250 shares of the biopharmaceutical company’s stock worth $190,000 after buying an additional 1,700 shares in the last quarter. 84.53% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece of content was first published by BNB Daily and is owned by of BNB Daily. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.baseball-news-blog.com/2017/08/19/agios-pharmaceuticals-inc-agio-given-average-rating-of-buy-by-brokerages-updated-updated-updated.html.
Agios Pharmaceuticals (NASDAQ:AGIO) opened at 58.26 on Monday. Agios Pharmaceuticals has a 1-year low of $35.84 and a 1-year high of $67.74. The firm’s market cap is $2.81 billion. The company’s 50-day moving average price is $56.86 and its 200 day moving average price is $51.74.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.57) by $0.21. Agios Pharmaceuticals had a negative return on equity of 68.15% and a negative net margin of 502.12%. The company had revenue of $11.30 million during the quarter, compared to analyst estimates of $10.68 million. During the same period last year, the company posted ($1.47) earnings per share. The company’s revenue was up 62.1% compared to the same quarter last year. On average, equities analysts expect that Agios Pharmaceuticals will post ($6.90) earnings per share for the current fiscal year.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.